surpass 2 tirzepatide versus Semaglutide in Type Diabetes (SURPASS-2) | NEJM | Med Journal Club SURPASS-CVOT trial results: Tirzepatide's impact

Patients who are pregnant or breastfeeding, have active cancer or a recent cancer history, or are on immunosuppressive medication should not use KPV

This cellular hydration shift helps create an anabolic environment to support muscle retention

GLP-1 is released in the intestine after food intake and helps to regulate blood sugar levels

Both GIP receptor agonism and antagonism were able to reduce body weight or prevent diet-induced obesity in mice [18]

View our Privacy Policy and Terms & Conditions Attend our FREE open evening If you're not sure which course is right for you, let us help Join us online or in-person at our free open evening to learn more Our Partners STAY INFORMED Sign up to receive industry news, careers advice, special offers and information on Harley Academy courses and services